PEA Plus Capsules

PEA Plus Dual Action Pain Relief

PEA Plus is a dual-action pain relief formula containing scientifically proven Levagen®+ (highly bioavailable PEA) and HydroCurc® (a unique bioavailable form of curcumin) combined in vege capsules. With up to 90% absorption activity, PEA Plus exerts a fast-acting endocannabinoid-like effect for analgesic, anti-inflammatory, anxiolytic and neuroprotective support for in-clinic use.

• Dual Action: 2 scientifically researched ingredients: PEA (Levagen®+) and Curcumin (HydroCurc®).
• High Absorption: Up to 90% absorption, compared with standard PEA and Curcumin.
• Fast Acting - Levagen, acts as a highly bioavailable form of PEA. Acting with LipiSperse ™ technology for fast effective absorption with enhanced effect.
• Management of wide range of symptoms: Multi benefits for pain, immunity and autoimmunity, sleep and more. Having a total pain relief effect on complete well-being.
• High safety profile: Low-risk liver toxicity.

Practitioner Only Capsules

Size: 60 vege capsules

Dosage: (Adults)
Maintenance: 1 to 2 capsules daily.
Acute: 2 capsules, twice daily.

ACTIVE INGREDIENTS PER VEGETABLE CAPSULE

Levagen®+ (PEA)                              150 mg
HydroCurc® (Curcumin)                 150 mg

Contains encapsulating aids.

Actions: Analgesic, Anti-inflammatory, Anxiolytic, Neuroprotective, Relaxant

Main indication: Acute/chronic inflammatory conditions, Neuralgia conditions, Fatigue, Body and musculoskeletal pain, Headaches, Joint pain and mobility, Injury and exercise recovery, Sleep issues (insomnia)

Safety information: Not suitable for use in pregnancy.

Please seek advice of a healthcare professional if currently on any anti-coagulant medication.

More Information: Technical Sheet. FAQs

Research Articles:
The Effect of Orally Dosed Levagen+™ (palmitoylethanolamide) on Exercise Recovery in Healthy Males-A Double-Blind, Randomized, Placebo-Controlled Study (2020)
Increased Absorption of Palmitoylethanolamide Using a Novel Dispersion Technology System (LipiSperse®) (2020)
A double‑blind randomized placebo controlled study assessing safety, tolerability and efficacy of palmitoylethanolamide for symptoms of knee osteoarthritis (2019)
Ultra-micronized Palmitoylethanolamide: An Efficacious Adjuvant Therapy for Parkinson’s Disease (2007)